You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

COVID-19: Get the latest updates or take a self-assessment.

 

1545 Results
Regimen
Cancer Type:
Hematologic, 
Multiple Myeloma
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
ODB Limited Use
    lenalidomide - For the treatment of patients with multiple myeloma, who are deemed to be lenalidomide sensitive, and/or has not experienced progression while on a lenalidomide-based regimen in a treatment or maintenance setting, according to clinical criteria
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
bortezomib (Unfunded),
lenalidomide
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Jun 2022
Regimen
Cancer Type:
Head and Neck, 
Nasopharynx
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Drugs Used:
tislelizumab (Unfunded),
gemcitabine,
CISplatin
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Apr 2024
Regimen
Cancer Type:
Hematologic, 
Multiple Myeloma
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
New Drug Funding Program
    Carfilzomib (Doublet Therapy) - In Combination with Dexamethasone for Relapsed Multiple Myeloma
ODB - General Benefit
    dexamethasone
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
carfilzomib,
dexamethasone
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Jun 2024
Regimen
Cancer Type:
Gynecologic, 
Gestational Trophoblastic Disease
Show More Show more tags
, Show Less Show fewer tags
Intent: Curative
Drugs Used:
DACTINomycin
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Jun 2020
Regimen
Cancer Type:
Central Nervous System
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
ODB - General Benefit
    lomustine
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
lomustine
... Show more tags
, Collapse Show fewer tags
Jun 2019
Regimen
Cancer Type:
Head and Neck
Show More Show more tags
, Show Less Show fewer tags
Intent: Adjuvant, Palliative
Drugs Used:
CARBOplatin,
fluorouracil
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Apr 2023
Regimen
Cancer Type:
Head and Neck
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Drugs Used:
CISplatin,
cetuximab (Unfunded)
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Aug 2019
Regimen
Cancer Type:
Hematologic, 
Multiple Myeloma
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
ODB - General Benefit
    cyclophosphamide - oral tablets
ODB - General Benefit
    dexamethasone
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
cyclophosphamide,
dexamethasone,
lenalidomide (Unfunded)
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
May 2022
Regimen
Cancer Type:
Gastrointestinal, 
Hepatobiliary / Liver / Bile Duct
Show More Show more tags
, Show Less Show fewer tags
Intent: Adjuvant
Drugs Used:
fluorouracil
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Apr 2023
Regimen
Cancer Type:
Hematologic, 
Lymphoma - Non-Hodgkin's Intermediate Grade
Show More Show more tags
, Show Less Show fewer tags
Intent: Curative
Funding:
New Drug Funding Program
    Rituximab (Biosimilar IV) - As Part of the MATRix Regimen in Newly Diagnosed Previously Untreated PCNSL
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
riTUXimab,
methotrexate,
cytarabine,
thiotepa
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Jan 2023
Regimen
Cancer Type:
Gastrointestinal, 
Small bowel and appendix
Show More Show more tags
, Show Less Show fewer tags
Intent: Neoadjuvant
Funding:
ODB - General Benefit
    capecitabine
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
capecitabine
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Apr 2023
Regimen
Cancer Type:
Hematologic, 
Multiple Myeloma
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
New Drug Funding Program
    Bortezomib - Previously Untreated - Multiple Myeloma Pre-Stem Cell Transplant
ODB - General Benefit
    dexamethasone
ODB - General Benefit
    cyclophosphamide - oral tablets
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
bortezomib,
pegylated liposomal DOXOrubicin (Unfunded),
dexamethasone,
cyclophosphamide
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Sep 2019

Pages